Kali-chemie Pharma Gmbh

Klaus-Ullrich Wolf

Horst Zeugner

Henning Heinemann

Wolfgang Milkowski

Hans Liepmann

Insa Hell

Heinrich-Wilhelm Ohlendorf

Rolf Hueschens

Reinhard Hempel

Wilhelm Kaupmann

Wolfgang Kehrbach

Werner Benson

Ineke Van Wijngaarden

Uwe Schoen

Ulf Preuschoff

Michael Ruhland

Uwe Schon

Martin Tulp

Peter-Colin Gregory

Derk Hamminga

Karin Van Charldorp

Peter C Gregory

Harald Waldeck

Ton Hulkenberg

Pharmacologically active compounds corresponding to the general formula I ##STR1## in which R.sup.1 represents hydrogen, a lower alkyl or cycloalkyl-alkyl group or an optionally substituted phenyl-lower alkyl group,

6-oxoazepinoindole compounds, and pharmaceutical compositions containing

Compounds corresponding to the formula I ##STR1## in which R.sup.1 represents hydrogen, lower alkyl or cycloalkylalkyl with 4-7 carbon atoms,

1,7-fused 1H-indole-2-carboxylic acid-N-(1,4-benzodiazepin-3-yl)amides

3-sulfonyl-3,7-diazabicyclo[3,3,1]nonane compounds corresponding to the formula: ##STR1## wherein R.sup.1 is alkyl, cycloalkylalkyl or benzyl,

3-sulfonyl-3,7-diazabicyclo[3,3,1]nonane intermediates and

3-sulfonyl-3,7-diazabicyclo[3,3,1]nonane compounds and medicaments

3-amino-2,3-dihydro-1-benzoxepine compounds corresponding to the general Formula I ##STR1## wherein R.sub.1 and R.sub.2 may each be hydrogen, halogen, lower alkyl or lower alkoxy, or if one of R.sub.1 and R.sub.2 is hydrogen, the other may also be nitro or trifluoromethyl, R.sub.3 represents hydrogen or a lower alkyl group which optionally may be substituted by hydroxy, lower alnoxy, an optionally substituted phenyl group or an optionally substituted amino group, and R.sub.4 represents hydrogen or lower alkyl, or R.sub.3 and R.sub.4 together with the nitrogen atom form a 5 or 6 member heterocycle. The compounds exhibit pharmacological, especially antidepressive, activity.

3-amino-2,3-dihydro-1-benzoxepine compounds and pharmaceutical

N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols are disclosed which possess ulcer-inhibiting activities. Further disclosed are pharmaceutical compositions which are effective in the treatment and prophylaxis of ulcers and which comprise as a pharmacologically active ulcus-inhibiting ingredient N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols, or a pharmaceutically acceptable acid addition salt thereof, and a pharmaceutically acceptable diluent. Further disclosed are processes for the preparation of the N.sub.1 -acyl-N.sub.2 -phenyl-1,3-diaminopropan-2-ols.

N.sub.1 -Acyl-N.sub.2 -phenyl-diaminopropanols and pharmaceutical

Compounds of [1,2]anellated-7-phenyl-1,4-benzodiazepines having the formula I ##STR1## wherein X is oxygen, sulfur or NR;

[1,2]Anellated-7-phenyl-1,4-benzodiazepine and pharmaceutical

Novel, 3-amino-1-benzoxepin-5(2H)-one derivatives and methods for their production are disclosed. These derivatives correspond to the Formula I: ##STR1## wherein: R.sub.1 and R.sub.2 independently of one another are hydrogen,

2,3,4,5-Tetrahydro-1-benzoxepin-3,5-dione derivatives

Novel, 3-amino-1-benzoxepin-5 (2H)-one derivatives and methods for their production are disclosed. These derivatives correspond to the Formula I: ##STR1## wherein: R.sub.1 and R.sub.2 independently of one another are

1-Benzoxepin-5 (2H)-one derivatives and pharmaceutical compositions

Novel 3-amino-1-benzoxepine derivatives and methods for their production are disclosed. These derivatives correspond to the Formula I ##STR1## wherein: R.sub.1 and R.sub.2 independently of one another are

3-Amino-1-benzoxepine derivatives and their salts and pharmaceutical

N.sub.1 -acyl-N.sub.2 -phenyldiaminopropanols and pharmaceutical

Pharmaceutical compositions are disclosed, which are effective in the treatment and prophylaxis of ulcers and which comprise as a pharmacologically active ulcus-inhibiting ingredient a compound selected from the group of N.sub.1 -acyl-N.sub.2 -(4-chlorophenyl)-1,3-diaminopropan-2-ols, having the formula I ##STR1## wherein R.sub.1 represents 3,4-dimethoxyphenyl, 2-fluorophenyl, 2-trifluoromethylphenyl, or furyl, and pharmaceutically acceptable acid addition salts thereof, and a pharmaceutically acceptable diluent. Further disclosed is a new process for the preparation of the compounds of formula I.

Growing community of inventors

Haenigsen, Germany

Klaus-Ullrich Wolf